ProMIS Neurosciences, Inc.
- Open
- 12.81
- Day high
- 13.76
- Day low
- 12.40
- Prev close
- 13.16
- Volume
- 6K
- Mkt cap
- $120M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 2.0
- P/S
- —
- Yield
- —
- Per share
- —
- ▲Insiders net buying $45K over the last 3 months (1 open-market buy, 0 sales)
- 🏛Institutions accumulating (13F)
ProMIS Neurosciences, Inc. (PMN) is a Healthcare company listed on NASDAQ. The stock is up 10% over the past year. Over the trailing 3 months, insiders filed 1 open-market buy and 0 sales (SEC Form 4).
ProMIS Neurosciences, Inc. (PMN) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
PMN earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 12, 2026 | $-1.06 | $-1.26 | -18.9% | — | — |
| Mar 25, 2026 | $-4.66 | $-4.11 | +11.8% | — | — |
| Nov 12, 2025 | $-3.75 | $-6.00 | -60.0% | — | — |
| Aug 13, 2025 | $-0.22 | $-0.29 | -31.8% | — | — |
| Mar 31, 2025 | $-0.14 | $-0.02 | +85.7% | — | — |
| Nov 14, 2024 | $-0.07 | $-0.14 | -100.0% | — | — |
| Aug 8, 2024 | $-0.14 | $-0.13 | +7.1% | — | — |
| Apr 1, 2024 | $-0.17 | $-0.09 | +47.1% | $4725 | — |
| Nov 14, 2023 | $-0.33 | $-0.19 | +42.4% | — | — |
| Aug 14, 2023 | — | $-0.27 | — | — | — |
| May 15, 2023 | — | $-0.58 | — | — | — |
| Mar 8, 2023 | — | $-0.90 | — | $-3109 | — |
PMN insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| May 22, 2026 | WYMAN WILLIAM Wdirector | Grant | 5,500 | $10.77 |
| May 22, 2026 | Alex Slanix Pauldirector | Grant | 11,000 | $10.77 |
| May 22, 2026 | Alex Slanix Pauldirector | Grant | 5,500 | $10.77 |
| May 22, 2026 | Kaplan Johanneofficer: Chief Development Officer | Grant | 50,000 | $10.77 |
| May 22, 2026 | Mandel-Brehm Joshdirector | Grant | 11,000 | $10.77 |
| May 22, 2026 | Mandel-Brehm Joshdirector | Grant | 5,500 | $10.77 |
| May 22, 2026 | Milbury Max A.officer: Principal Accounting Officer | Grant | 18,167 | $10.77 |
| May 22, 2026 | Cashman Neildirector, officer: Chief Scientific Officer | Grant | 50,000 | $10.77 |
| May 22, 2026 | Shafmaster Madge K.director | Grant | 11,000 | $10.77 |
| May 22, 2026 | Shafmaster Madge K.director | Grant | 5,500 | $10.77 |
| May 22, 2026 | Warma Neil Kdirector, officer: Chief Executive Officer | Grant | 160,000 | $10.77 |
| May 22, 2026 | Williams Eugenedirector | Grant | 11,000 | $10.77 |
| May 22, 2026 | Williams Eugenedirector | Grant | 5,500 | $10.77 |
| May 22, 2026 | WYMAN WILLIAM Wdirector | Grant | 11,000 | $10.77 |
| Apr 23, 2026 | Kirwin Patrick D.director | Buy | 4,000 | $11.33 |
Source: PMN SEC Form 4 filings, latest May 22, 2026. For informational purposes only — not investment advice.
See the full PMN insider & 13F page →ProMIS Neurosciences, Inc. company profile
Overview
ProMIS Neurosciences, Inc. (NASDAQ:PMN) is a Canadian biotechnology company founded in 2004 and headquartered in Toronto. Originally incorporated as Amorfix Life Sciences Ltd., the company rebranded to ProMIS Neurosciences in July 2015 to better reflect its focus on precision medicine for neurodegenerative diseases. The company went public in 2007 and currently trades on NASDAQ. ProMIS specializes in developing targeted therapies for devastating neurological conditions including Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and multiple system atrophy, using proprietary computational algorithms to identify novel drug targets.
Business
ProMIS Neurosciences operates in the biotechnology sector, specifically focusing on precision medicine solutions for neurodegenerative diseases. The company's core innovation lies in its proprietary computational discovery platform that combines two sophisticated algorithms: ProMIS and Collective Coordinates. These algorithms analyze the molecular structure of misfolded proteins—abnormal protein formations that are hallmarks of neurodegenerative diseases—to predict novel targets called disease-specific epitopes on their surfaces. Neurodegenerative diseases occur when neurons progressively deteriorate and die, leading to conditions like Alzheimer's disease (memory loss and cognitive decline), ALS (muscle weakness and paralysis), and multiple system atrophy (movement and autonomic function problems). A key feature of these diseases is the accumulation of misfolded proteins that form toxic clumps in the brain and nervous system. Traditional drug development approaches have largely failed because they target the wrong parts of these proteins or fail to distinguish between toxic and non-toxic forms. The company's drug pipeline consists of three main monoclonal antibody candidates: 1. PMN310 targets toxic oligomers (small protein clumps) associated with Alzheimer's disease. Oligomers are particularly dangerous because they can spread between brain cells and cause widespread neuronal damage before larger plaques form. 2. PMN267 is designed to target multiple misfolded proteins including superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha-synuclein in Parkinson's disease and Lewy body dementia. This multi-target approach reflects the company's understanding that these diseases often involve multiple protein abnormalities. 3. PMN442 focuses on toxic alpha-synuclein oligomers and seeding fibrils in multiple system atrophy, a rare but devastating neurodegenerative condition. All three candidates are monoclonal antibodies, which are laboratory-produced molecules designed to bind to specific targets with high precision, potentially offering therapeutic benefits while minimizing side effects.
Revenue model
ProMIS Neurosciences operates as a pre-revenue biotechnology company, meaning it currently generates no product sales revenue. The company's business model is built around developing proprietary drug candidates through clinical trials with the ultimate goal of either licensing these assets to larger pharmaceutical companies or bringing them to market independently. The company's revenue model will eventually depend on several potential streams: licensing fees and milestone payments from pharmaceutical partners, royalties from commercialized products, and potentially direct product sales if the company chooses to commercialize drugs independently. However, given the capital-intensive nature of bringing drugs to market, most biotechnology companies at ProMIS's stage typically partner with larger pharmaceutical companies that have the resources and infrastructure for global commercialization. The company's current funding comes primarily from equity financing, as evidenced by periodic capital raises. The financial statements show significant cash burn with no offsetting revenue, which is typical for companies in the drug development phase. Operating expenses primarily consist of research and development costs, regulatory affairs, and general administrative expenses. Several factors could significantly impact the company's future profitability margins. Regulatory success is paramount—positive clinical trial results and eventual FDA approval would dramatically increase the company's valuation and partnership potential. Competition in the neurodegenerative disease space is intense, with major pharmaceutical companies and other biotechnology firms pursuing similar targets. Intellectual property strength will be crucial for maintaining competitive advantages and commanding premium licensing terms. Manufacturing costs for monoclonal antibodies can be substantial, though economies of scale typically improve margins for successful products. Finally, market size and pricing power will depend on the severity of the conditions treated and the availability of alternative therapies, with neurodegenerative diseases generally commanding premium pricing due to high unmet medical need.
Competitive moat
ProMIS Neurosciences' competitive moat is primarily built around its proprietary computational discovery platform and the specific epitopes it has identified on misfolded proteins. The company's ProMIS and Collective Coordinates algorithms represent a differentiated approach to target identification in neurodegenerative diseases, potentially allowing the company to identify therapeutic targets that competitors might miss using traditional discovery methods. However, the strength of this moat is questionable for several reasons. First, computational drug discovery is becoming increasingly common in biotechnology, with many companies developing sophisticated algorithms and AI-based approaches. The competitive advantage may be temporary as larger pharmaceutical companies with greater resources develop similar or superior computational capabilities. Second, the company's intellectual property portfolio around its specific targets and algorithms provides some protection, but patent landscapes in biotechnology are complex and competitors may find alternative approaches to similar targets. The company has not yet proven that its computationally-identified targets will translate into clinically superior drugs compared to traditional approaches. The most significant competitive threat comes from well-funded pharmaceutical giants like Roche, Biogen, and Eli Lilly, which have extensive resources for neurodegenerative disease research and established relationships with regulatory agencies. These companies can pursue multiple approaches simultaneously and have the financial staying power to weather clinical trial failures. Additionally, the field faces potential disruption from entirely different therapeutic modalities, such as gene therapy, cell therapy, or novel drug delivery systems that might bypass the need for traditional monoclonal antibodies altogether. The company's moat appears narrow and potentially temporary, dependent primarily on execution speed and the clinical success of its specific approach rather than sustainable competitive advantages.
Risks & safety
ProMIS Neurosciences presents significant financial risks with limited margin of safety: • Cash position: $8.4 million in cash and short-term investments as of Q1 2025, down from $13.3 million in Q4 2024 • Burn rate: Approximately $4.9 million quarterly cash burn from operations, suggesting roughly 1.7 quarters of runway at current spending levels • Debt level: Zero debt, which eliminates solvency pressure from interest payments • Current ratio: 3.36, indicating adequate short-term liquidity coverage • Valuation metrics: Negative earnings make traditional valuation difficult; trading at 2.56x book value • Market cap: Approximately $15.6 million, reflecting high speculative risk • Revenue: Zero revenue across all reported periods, typical for pre-clinical biotechnology companies • Additional considerations: Company will likely need additional financing within 6-12 months, which could result in significant dilution for existing shareholders. Success is entirely dependent on clinical trial outcomes, regulatory approval, and eventual partnership or commercialization.
Recent development
Based on the available financial data, ProMIS Neurosciences has experienced significant financial volatility over recent years, reflecting the inherent uncertainty in biotechnology development. The company's financial position has fluctuated considerably, with notable changes in cash levels and net income across reporting periods. A significant development occurred in Q3 2024 when the company reported a positive net income of $9.3 million, contrasting sharply with typical quarterly losses. This unusual positive result suggests either a one-time gain, potentially from asset sales, licensing agreements, or accounting adjustments, though specific details are not available from the financial statements alone. The company's cash position has varied substantially, reaching a high of approximately $21.5 million in Q3 2024 before declining to $8.4 million by Q1 2025. This pattern suggests the company may have completed a financing round or received significant payments in 2024, followed by continued operational cash burn. Throughout this period, the company has maintained its focus on developing its three primary drug candidates—PMN310 for Alzheimer's disease, PMN267 for ALS and other neurodegenerative conditions, and PMN442 for multiple system atrophy. The consistent zero revenue across all periods indicates the company remains in the pre-clinical or early clinical development phase, with no commercial partnerships or product sales yet realized. The company's operational strategy appears to center on advancing these candidates through clinical trials while seeking strategic partnerships or licensing opportunities with larger pharmaceutical companies, which is typical for biotechnology companies of this size and stage.
PMN company profile · for informational purposes only — not investment advice.
Track PMN with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free